Kite Reports P-I/II Study (ZUMA-3) Results of Tecartus (brexucabtagene autoleucel) for B-Cell Acute Lymphoblastic Leukemia
Shots:
- The 3yr. follow-up results from the P-I/II study (ZUMA-3) evaluating Tecartus (CAR T-cell therapy) in adult patients aged ≥18yrs.
- In the P-II treated patient cohort with the median follow-up (38.8mos.), OS rate (47.1%) @36.0mos. with a median OS of 26.0mos., CR or Cri was 38.9mos., responses remained durable with a consistent safety profile observed. Overall CR rate (CR + CRi)/CR/subsequent alloSCT rates remained unchanged (71%/56%/20%), respectively & m-RFS at subsequent alloSCT (11.6 & 11.7mos.)
- In P-I & II with the median follow-up (41.6mos.), m-DOR at subsequent alloSCT (18.6 & 20.0mos.), m-RFS (11.7mos.), 36% were alive with an m-OS (25.6mos.) with no grade 5 AEs were reported. The results were presented at the 5th EU CAR T-cell meeting
Ref: Businesswire | Image: Kite
Related News:- Kite Receives CHMP Positive Opinion of Tecartus (brexucabtagene autoleucel) for Relapsed or Refractory Acute Lymphoblastic Leukemia
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
